Doptelet (Avatrombopag Maleate) Patent Expiration, LOE Window & CMS Spending
Doptelet (Avatrombopag Maleate) by Akarx: FDA Orange Book core substance LOE 2027-07-28 (last listed 2032-07-24), 0 AB generics, $196.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Akarx |
| FDA Application & Pathway | N210238 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2027-07-28 |
| Last Listed Patent or Exclusivity Date | 2032-07-24 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $196.1M |
| 2024 Medicare Part D Spend | $159.7M |
| 2024 Medicaid Spend | $36.4M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 20.1% 2-yr change) |